Kane Biotech Appoints Dr. Jeffrey B. Kaplan to Scientific Advisory Board
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 07/20/10 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the appointment of Dr. Jeffrey B. Kaplan to its Scientific Advisory Board.
Dr. Jeffrey B. Kaplan is an Associate Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey and the discoverer of the antibiofilm enzyme DispersinB®. Dr. Kaplan's lab is a world leader in studying the inhibition, detachment and sensitization of bacterial biofilm cells with the emphasis of his research on the use of biofilm matrix-degrading enzymes as research tools and potential antibiofilm therapies.
"Dr. Kaplan has been a key contributor in the global fight against biofilms and in the advancement of Kane Biotech's biofilm technology," stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech. "We are pleased to formalize our relationship with Dr. Kaplan and welcome him to our scientific advisory board. His expertise in antibiofilm science is a valuable addition to our team of technical resources which includes recognized experts in microbiology, molecular biology and pharmacology."
Dr. Kaplan joins other members of Kane Biotech's Scientific Advisory Board
and technical resources including:
-- Dr. Tony Romeo, Professor, Microbiology and Cell Science, University of
Florida, a world-renowned expert in biofilm microbiology and global
regulator gene technology and the discoverer of Kane Biotech's first in-
licensed biofilm technology.
-- Dr. Dennis Cvitkovitch, Professor and Associate Dean (Research),
Director of the Dental Research Institute, Faculty of Dentistry,
University of Toronto, the discoverer of Kane Biotech's CSP technology
and a well respected researcher focused on cell-to-cell signaling,
biofilm formation and genetic exchange.
-- Dr. George Zhanel, Professor, Medical Microbiology, University of
Manitoba and Coordinator of Antibiotic Resistance in the Departments of
Medicine and Microbiology at the Health Sciences Centre in Winnipeg, an
internationally recognized authority on antibiotic resistance and member
of Kane Biotech's Board of Directors.
About Dr. Jeffrey B. Kaplan
Dr. Kaplan received a Bachelor of Science degree in Biology from the University of Illinois at Chicago in 1980 and a Ph.D. in Molecular Biology from the same institution in 1985. He received postdoctoral training in the Department of Microbiology at the Albert Einstein College of Medicine, Bronx, N.Y., and in the Department of Microbiology at Columbia University, College of Physicians and Surgeons, New York, N.Y. Dr. Kaplan worked for 10 years in the Oncology Department at Wyeth Pharmaceuticlas, Pearl River, N.Y., before joining the Department of Oral Biology at New Jersey Dental School in 1999. Dr. Kaplan's research is supported by prestigious institutions such as the National Institute of Allergies and Infectious Diseases, the National Institute of Dental and Craniofacial Research, the University of Medicine and Dentistry of New Jersey Foundation and Genentech, Inc.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Gord Froehlich President & Chief Executive Officer 204-477-7592 204-453-1314 (FAX) ir@kanebiotech.com www.kanebiotech.com
Released July 20, 2010